Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

The narrative paradox of the BRCA gene: an ethnographic study in the clinical encounters of ovarian cancer patients.

Therond C, Lanceley A, Gibbon S, Rahman B.

Anthropol Med. 2020 Feb 3:1-16. doi: 10.1080/13648470.2019.1663784. [Epub ahead of print]

PMID:
32009452
2.

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Roncolato FT, O'Connell RL, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler MR, King MT, Friedlander ML.

Gynecol Oncol. 2020 Jan;156(1):45-53. doi: 10.1016/j.ygyno.2019.10.001. Epub 2019 Dec 10.

PMID:
31836184
3.

Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process.

McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L, Lanceley A.

Int J Gynecol Cancer. 2020 Feb;30(2):221-226. doi: 10.1136/ijgc-2019-000630. Epub 2019 Nov 19.

PMID:
31744886
4.

Sensitivity to change of the EORTC quality of life module measuring cancer-related fatigue (EORTC QlQ-Fa12): Results from the international psychometric validation.

Weis J, Wirtz MA, Tomaszewski KA, Hammerlid E, Arraras JI, Conroy T, Lanceley A, Schmidt H, Singer S, Pinto M, Alm El-Din M, Compter I, Holzner B, Hofmeister D, Chie WC, Harle A, Flechtner HH, Bottomley A; EORTC Quality of Life Group.

Psychooncology. 2019 Aug;28(8):1753-1761. doi: 10.1002/pon.5151. Epub 2019 Jul 9.

PMID:
31225669
5.

Consent in pregnancy: A qualitative study of the views and experiences of women and their healthcare professionals.

Nicholls J, David AL, Iskaros J, Lanceley A.

Eur J Obstet Gynecol Reprod Biol. 2019 Jul;238:132-137. doi: 10.1016/j.ejogrb.2019.05.008. Epub 2019 May 11.

PMID:
31129561
6.

Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials.

Kyte D, Retzer A, Ahmed K, Keeley T, Armes J, Brown JM, Calman L, Gavin A, Glaser AW, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Efficace F, Mercieca-Bebber R, King MT, Turner G, Calvert M.

J Natl Cancer Inst. 2019 Nov 1;111(11):1170-1178. doi: 10.1093/jnci/djz038.

7.

Stepped approach to improving sexual function after gynaecological cancer: the SAFFRON feasibility RCT.

Gessler S, King M, Lemma A, Barber J, Jones L, Dunning S, Madden V, Pilling S, Hunter R, Fonagy P, Summerville K, MacDonald N, Olaitan A, Lanceley A.

Health Technol Assess. 2019 Feb;23(6):1-92. doi: 10.3310/hta23060.

8.

Diet, physical activity, and health-related outcomes of endometrial cancer survivors in a behavioral lifestyle program: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomized controlled pilot trial.

Koutoukidis DA, Beeken RJ, Manchanda R, Burnell M, Ziauddeen N, Michalopoulou M, Knobf MT, Lanceley A.

Int J Gynecol Cancer. 2019 Mar;29(3):531-540. doi: 10.1136/ijgc-2018-000039. Epub 2019 Feb 4.

9.

Mentalization in CALM psychotherapy sessions: Helping patients engage with alternative perspectives at the end of life.

Shaw C, Chrysikou V, Lanceley A, Lo C, Hales S, Rodin G.

Patient Educ Couns. 2019 Feb;102(2):188-197. doi: 10.1016/j.pec.2018.10.001. Epub 2018 Oct 3.

PMID:
30482609
10.

Attitudes towards a programme of risk assessment and stratified management for ovarian cancer: a focus group study of UK South Asians' perspectives.

Hann KEJ, Ali N, Gessler S, Fraser LSM, Side L, Waller J, Sanderson SC, Lanceley A; PROMISE study team.

BMJ Open. 2018 Jul 18;8(7):e021782. doi: 10.1136/bmjopen-2018-021782.

11.

Differences in health care professionals' and cancer patients' views on sexual health issues.

Greimel E, Lanceley A, Oberguggenberger A, Nordin A, Kuljanic K, Schmalz C, Arraras JI, Chie W, Jensen PT, Tomaszewski KA, Creutzberg CL, Galalae R, Toelen H, Inwald EC, Bjelic-Radisic V; EORTC Quality of Life Group.

Psychooncology. 2018 Sep;27(9):2299-2302. doi: 10.1002/pon.4814. Epub 2018 Jul 3. No abstract available.

PMID:
29927000
12.

Use of intervention mapping to adapt a health behavior change intervention for endometrial cancer survivors: the shape-up following cancer treatment program.

Koutoukidis DA, Lopes S, Atkins L, Croker H, Knobf MT, Lanceley A, Beeken RJ.

BMC Public Health. 2018 Mar 27;18(1):415. doi: 10.1186/s12889-018-5329-5.

13.

Mainstreamed genetic testing for women with ovarian cancer: first-year experience.

Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L.

J Med Genet. 2019 Mar;56(3):195-198. doi: 10.1136/jmedgenet-2017-105140. Epub 2018 Mar 13.

PMID:
29535157
14.

Phase 1-3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22.

Oberguggenberger AS, Nagele E, Inwald EC, Tomaszewski K, Lanceley A, Nordin A, Creutzberg CL, Kuljanic K, Kardamakis D, Schmalz C, Arraras J, Costantini A, Almont T, Wei-Chu C, Dehandschutter S, Winters Z, Greimel E; EORTC Quality of Life Group.

Cancer Med. 2018 Mar;7(3):635-645. doi: 10.1002/cam4.1338. Epub 2018 Feb 13.

15.

Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.

Retzer A, Keeley T, Ahmed K, Armes J, Brown JM, Calman L, Copland C, Efficace F, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M, Kyte D.

BMJ Open. 2018 Feb 3;8(2):e017282. doi: 10.1136/bmjopen-2017-017282.

16.

Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review.

Froeding LP, Greimel E, Lanceley A, Oberguggenberger A, Schmalz C, Radisic VB, Nordin A, Galalaei R, Kuljanic K, Vistad I, Schnack TH, Jensen PT; European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group.

Int J Gynecol Cancer. 2018 May;28(4):808-817. doi: 10.1097/IGC.0000000000001211.

PMID:
29420364
17.

Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK.

Meisel SF, Fraser LSM, Side L, Gessler S, Hann KEJ, Wardle J, Lanceley A; PROMISE study team.

BMJ Open. 2017 Dec 22;7(12):e017675. doi: 10.1136/bmjopen-2017-017675.

18.

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.

Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.

PMID:
29248998
19.

Health care professionals' attitudes towards population-based genetic testing and risk-stratification for ovarian cancer: a cross-sectional survey.

Hann KEJ, Fraser L, Side L, Gessler S, Waller J, Sanderson SC, Freeman M, Jacobs I, Lanceley A; PROMISE study team.

BMC Womens Health. 2017 Dec 16;17(1):132. doi: 10.1186/s12905-017-0488-6.

20.

Impact of a decision aid about stratified ovarian cancer risk-management on women's knowledge and intentions: a randomised online experimental survey study.

Meisel SF, Freeman M, Waller J, Fraser L, Gessler S, Jacobs I, Kalsi J, Manchanda R, Rahman B, Side L, Wardle J, Lanceley A, Sanderson SC; PROMISE team.

BMC Public Health. 2017 Nov 16;17(1):882. doi: 10.1186/s12889-017-4889-0.

21.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).

Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M.

Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26.

PMID:
29107348
22.

Recruitment, adherence, and retention of endometrial cancer survivors in a behavioural lifestyle programme: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomised pilot trial.

Koutoukidis DA, Beeken RJ, Manchanda R, Michalopoulou M, Burnell M, Knobf MT, Lanceley A.

BMJ Open. 2017 Oct 8;7(10):e018015. doi: 10.1136/bmjopen-2017-018015.

23.

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.

Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group.

Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047. Epub 2017 Jun 8.

24.

Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review.

Hann KEJ, Freeman M, Fraser L, Waller J, Sanderson SC, Rahman B, Side L, Gessler S, Lanceley A; PROMISE study team.

BMC Public Health. 2017 May 25;17(1):503. doi: 10.1186/s12889-017-4375-8. Review.

25.

International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12).

Weis J, Tomaszewski KA, Hammerlid E, Ignacio Arraras J, Conroy T, Lanceley A, Schmidt H, Wirtz M, Singer S, Pinto M, Alm El-Din M, Compter I, Holzner B, Hofmeister D, Chie WC, Czeladzki M, Harle A, Jones L, Ritter S, Flechtner HH, Bottomley A; EORTC Quality of Life Group.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw273.

PMID:
28376231
26.

Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening.

Gentry-Maharaj A, Karpinskyj C, Glazer C, Burnell M, Bailey K, Apostolidou S, Ryan A, Lanceley A, Fraser L, Jacobs I, Hunter MS, Menon U.

Climacteric. 2017 Jun;20(3):240-247. doi: 10.1080/13697137.2017.1301919. Epub 2017 Mar 22.

27.

Moving towards population-based genetic risk prediction for ovarian cancer.

Rahman B, Side L, Gibbon S, Meisel SF, Fraser L, Gessler S, Wardle J, Lanceley A.

BJOG. 2017 May;124(6):855-858. doi: 10.1111/1471-0528.14603. No abstract available.

28.

Erratum to: Diet and exercise in uterine cancer survivors (DEUS pilot) - piloting a healthy eating and physical activity program: study protocol for a randomized controlled trial.

Koutoukidis DA, Beeken RJ, Manchanda R, Burnell M, Knobf MT, Lanceley A.

Trials. 2017 Jan 18;18(1):28. doi: 10.1186/s13063-017-1776-z. No abstract available.

29.

Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches.

Lanceley A, Berzuini C, Burnell M, Gessler S, Morris S, Ryan A, Ledermann JA, Jacobs I.

Int J Gynecol Cancer. 2017 Jan;27(1):59-68. doi: 10.1097/IGC.0000000000000877.

PMID:
28002208
30.

Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol.

Ahmed K, Kyte D, Keeley T, Efficace F, Armes J, Brown JM, Calman L, Copland C, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor R, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M.

BMJ Open. 2016 Sep 21;6(9):e012863. doi: 10.1136/bmjopen-2016-012863.

31.

Inviting end-of-life talk in initial CALM therapy sessions: A conversation analytic study.

Shaw C, Chrysikou V, Davis S, Gessler S, Rodin G, Lanceley A.

Patient Educ Couns. 2017 Feb;100(2):259-266. doi: 10.1016/j.pec.2016.08.024. Epub 2016 Aug 24.

PMID:
27632906
32.

Genetic testing and personalized ovarian cancer screening: a survey of public attitudes.

Meisel SF, Rahman B, Side L, Fraser L, Gessler S, Lanceley A, Wardle J; PROMISE-2016 study team.

BMC Womens Health. 2016 Jul 26;16:46. doi: 10.1186/s12905-016-0325-3.

33.

Attitudes, challenges and needs about diet and physical activity in endometrial cancer survivors: a qualitative study.

Koutoukidis DA, Beeken RJ, Lopes S, Knobf MT, Lanceley A.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12531. Epub 2016 Jun 21.

34.

Diet and exercise in uterine cancer survivors (DEUS pilot) - piloting a healthy eating and physical activity program: study protocol for a randomized controlled trial.

Koutoukidis DA, Beeken RJ, Manchanda R, Burnell M, Knobf MT, Lanceley A.

Trials. 2016 Mar 10;17(1):130. doi: 10.1186/s13063-016-1260-1. Erratum in: Trials. 2017 Jan 18;18(1):28.

35.

Use of a formal consensus development technique to produce recommendations for improving the effectiveness of adult mental health multidisciplinary team meetings.

Raine R, a' Bháird CN, Xanthopoulou P, Wallace I, Ardron D, Harris M, Barber J, Prentice A, Gibbs S, King M, Blazeby JM, Michie S, Lanceley A, Clarke A, Livingston G.

BMC Psychiatry. 2015 Jul 3;15:143. doi: 10.1186/s12888-015-0534-6.

36.

Obesity, diet, physical activity, and health-related quality of life in endometrial cancer survivors.

Koutoukidis DA, Knobf MT, Lanceley A.

Nutr Rev. 2015 Jun;73(6):399-408. doi: 10.1093/nutrit/nuu063. Epub 2015 Apr 7. Review.

37.

Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK.

Meisel SF, Pashayan N, Rahman B, Side L, Fraser L, Gessler S, Lanceley A, Wardle J.

Breast. 2015 Jun;24(3):237-41. doi: 10.1016/j.breast.2015.02.001. Epub 2015 Feb 21.

38.

Improving the effectiveness of multidisciplinary team meetings for patients with chronic diseases: a prospective observational study.

Raine R, Wallace I, Nic a’ Bháird C, Xanthopoulou P, Lanceley A, Clarke A, Prentice A, Ardron D, Harris M, Gibbs JSR, Ferlie E, King M, Blazeby JM, Michie S, Livingston G, Barber J.

Southampton (UK): NIHR Journals Library; 2014 Oct.

39.

Mixed methods evaluation of well-being benefits derived from a heritage-in-health intervention with hospital patients.

Paddon HL, Thomson LJ, Menon U, Lanceley AE, Chatterjee HJ.

Arts Health. 2014 Feb;6(1):24-58. Epub 2013 May 17.

40.

Population-based genetic risk prediction and stratification for ovarian cancer: views from women at high risk.

Rahman B, Meisel SF, Fraser L, Side L, Gessler S, Wardle J, Lanceley A.

Fam Cancer. 2015 Mar;14(1):135-44. doi: 10.1007/s10689-014-9769-5.

41.

Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study.

Gentry-Maharaj A, Karpinskyj C, Glazer C, Burnell M, Ryan A, Fraser L, Lanceley A, Jacobs I, Hunter MS, Menon U.

Menopause. 2015 Apr;22(4):384-90. doi: 10.1097/GME.0000000000000330.

42.

Determinants of treatment plan implementation in multidisciplinary team meetings for patients with chronic diseases: a mixed-methods study.

Raine R, Xanthopoulou P, Wallace I, Nic A' Bháird C, Lanceley A, Clarke A, Livingston G, Prentice A, Ardron D, Harris M, King M, Michie S, Blazeby JM, Austin-Parsons N, Gibbs S, Barber J.

BMJ Qual Saf. 2014 Oct;23(10):867-76. doi: 10.1136/bmjqs-2014-002818. Epub 2014 Jun 9.

43.
44.

Follow-up protocols for women with cervical cancer after primary treatment.

Lanceley A, Fiander A, McCormack M, Bryant A.

Cochrane Database Syst Rev. 2013 Nov 25;(11):CD008767. doi: 10.1002/14651858.CD008767.pub2. Review.

PMID:
24277645
45.

Population-based, risk-stratified genetic testing for ovarian cancer risk: a focus group study.

Meisel SF, Side L, Fraser L, Gessler S, Wardle J, Lanceley A.

Public Health Genomics. 2013;16(4):184-91. doi: 10.1159/000352028. Epub 2013 Jul 4.

46.

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T.

Lancet Oncol. 2013 Mar;14(3):236-43. doi: 10.1016/S1470-2045(12)70567-3. Epub 2013 Jan 18.

47.

Enhancing cancer patient well-being with a nonpharmacological, heritage-focused intervention.

Thomson LJ, Ander EE, Menon U, Lanceley A, Chatterjee HJ.

J Pain Symptom Manage. 2012 Nov;44(5):731-40. doi: 10.1016/j.jpainsymman.2011.10.026. Epub 2012 Jul 25.

48.

Noninvasive nutritional management of ovarian cancer patients: beyond intestinal obstruction.

Balogun N, Forbes A, Widschwendter M, Lanceley A.

Int J Gynecol Cancer. 2012 Jul;22(6):1089-95. doi: 10.1097/IGC.0b013e318256e4d3. Review.

PMID:
22688964
49.

Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13).

Weis J, Arraras JI, Conroy T, Efficace F, Fleissner C, Görög A, Hammerlid E, Holzner B, Jones L, Lanceley A, Singer S, Wirtz M, Flechtner H, Bottomley A.

Psychooncology. 2013 May;22(5):1002-7. doi: 10.1002/pon.3092. Epub 2012 May 4.

PMID:
22565359
50.

Family history and women with ovarian cancer: is it asked and does it matter?: An observational study.

Lanceley A, Eagle Z, Ogden G, Gessler S, Razvi K, Ledermann JA, Side L.

Int J Gynecol Cancer. 2012 Feb;22(2):254-9. doi: 10.1097/IGC.0b013e3182392714.

PMID:
22274317

Supplemental Content

Loading ...
Support Center